Friday, May 27 2022

SAN DIEGO, April 14, 2022 (GLOBE NEWSWIRE) — Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s president and CEO, will participate in a panel discussion at the Innovations in Women’s Health Business conference that will be held on April 21, 2022 at the Westin Copley Place in Boston, Massachusetts.








Sign: Femtech: emerging technology in the field of women’s health
Date: April 21, 2022
Weather: 4:00 p.m. to 5:00 p.m. Eastern Time
Speakers: Brittany Barreto, PhD, Moderator, Co-Founder and General Partner, Coyote Ventures and FemTech Focus
Tracy MacNeal, CEO, Materna Medical
Sabrina Martucci Johnson, President and CEO, Daré Bioscience
Juliette McClendon, PhD, Director of Medical Affairs at Big Health
Alicia Chong Rodriguez, Founder and CEO of Bloomer HealthTech
Details: This panel will focus on FemTech, which refers to the use of current and future technology to address the unique health needs of women or to manage a medical condition in women that has a different disease course. Participants will hear from founders, inventors and innovators in women’s health who will share their journey in FemTech and what the future holds regarding the impact of technology on women’s health. The integration of FemTech into women’s health services will also be discussed along with the achieved and projected results.

Additional conference information is available at https://xpectives.health/womens-health/

About Dare Bioscience

Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women’s health and well-being, expand treatment options and improve outcomes, primarily in the fields of contraception, fertility and vaginal and sexual health.

Daré’s first FDA-approved product, XACIATOMT (clindamycin phosphate vaginal gel, 2%) is an antibacterial lincosamide indicated for the treatment of bacterial vaginosis in patients 12 years of age and older. XACIATO is a clear, colorless and viscous gel, to be administered once intravaginally in a single dose. The Company’s pipeline also includes potential Tier 1 candidates in clinical development: Ovaprene®, a new hormone-free monthly contraceptive whose commercial rights in the United States are the subject of a licensing agreement with Bayer; Sildenafil Cream, 3.6%, a new formulation of Sildenafil Cream to treat Female Sexual Arousal Disorder using the active ingredient of Viagra®; and DARE-HRT1, a bioidentical combination of estradiol and intravaginal progesterone ring for hormone therapy after menopause. Learn more about XACIATOMTDaré’s comprehensive portfolio of product candidates for women’s health and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce important information about its financials, products and product candidates, clinical trials, and other matters by using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to disseminate important information about the company and may also use social media to communicate important information about the company, its finances, its products and product candidates, its clinical trials and other matters. Information that Daré posts on its investor relations website or via social media may be considered material information. Daré encourages investors, the media and others interested in the company to review information posted by Daré in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted to the Investors section of Daré’s website.

contacts:
Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan

[email protected]
212.213.0006

OR

Media on behalf of Daré Bioscience, Inc.:
Jake Robinson
Communications channel

[email protected]
619.849.5383

Source: Daré Bioscience, Inc.


main logo

Previous

Law Firm of Frank R. Cruz Announces Investigation of Apyx Medical Corporation (APYX) on Behalf of Investors

Next

SHAREHOLDER ACTION ALERT: Schall Law Firm Encourages Investors in Stronghold Digital Mining, Inc. Who Have Suffered $100,000 Losses to Contact the Firm

Check Also